- Home
- LENZ
as 05-20-2024 11:32am EST
$.
+$.
+.%
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
| Founded: | 2019 | Country: | Canada |
| Employees: | N/A | City: | DEL MAR |
| Market Cap: | 422.1M | IPO Year: | 2021 |
| Target Price: | $31.33 | AVG Volume (30 days): | 284.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | 44.10% | Dividend Payout Frequency: | N/A |
| EPS: | -15.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $24.59 | Next Earning Date: | 05-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest LENZ Therapeutics Inc. Common Stock News
LENZ Breaking Stock News: Dive into LENZ Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
19 days ago
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
Business Wire
2 months ago
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
Business Wire
2 months ago